Thymosin fraction 5 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | 28 residues; not a small-molecule compound |
| Molecular mass | About 3,106 Da | Monoisotopic mass of the unmodified chain |
| N-terminal group | Acetylated serine | Present in both native and synthetic forms |
| Secondary structure | Disulfide-constrained loop | One bridge between two cysteine residues |
| Typical source | Solid-phase synthesis | Early isolates came from bovine thymus extracts |
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
== Non-drug inhibitors == Many natural products (including anti-oxidants) that have been promoted to have anti-cancer and anti-inflammatory activity have also been shown to inhibit NF-κB. There is a controversial US patent (US patent 6,410,516) that applies to the discovery and use of agents that can block NF-κB for therapeutic purposes. This patent is involved in several lawsuits, including Ariad v. Lilly. Recent work by Karin, Ben-Neriah and others has highlighted the importance of the connection between NF-κB, inflammation, and cancer, and underscored the value of therapies that regulate the activity of NF-κB. Extracts from a number of herbs and dietary plants are efficient inhibitors of NF-κB activation in vitro. Nobiletin, a flavonoid isolated from citrus peels, has been shown to inhibit the NF-κB signaling pathway in mice. Likewise, various withanolides of Withania somnifera (Ashwagandha) have been found to have inhibiting effects on NF-κB through inhibition of proteasome mediated ubiquitin degradation of IκBα.
=== Duchies in the Danish realm === Between 500 and 1200, Schleswig was an integral part of Denmark, but during the 12th century, Duke Abel of Schlewig came into conflict with his brother King Eric IV. Abel managed to gain autonomy from his brother, making Schleswig an autonomous duchy. Later, Abel had Eric assassinated and seized the throne. Despite this, Schleswig remained an autonomous duchy within the Kingdom, setting the stage for future conflicts. Beginning in 1460, both the Duchy of Schleswig and Duchy of Holstein were ruled together by the Danish king, who acted as the duke of both regions. Holstein, being a duchy within the Holy Roman Empire, created a situation where the Danish king was sovereign of Denmark but also a duke within the Holy Roman Empire. Both were ruled for several centuries by the kings of Denmark. In 1721, all of Schleswig was united into a single duchy under the king of Denmark, and the great powers of Europe confirmed in an international treaty that all future kings of Denmark should automatically become dukes of Schleswig: consequently, Schleswig would always follow the order of succession that applied in the Kingdom of Denmark. After the Protestant Reformation, German was established as the language of commerce, administration, education, and clergy in Schleswig despite the population being ethnically Danish. This was because Schleswig was managed by the German Chancellery in Kiel, which was later renamed the Schleswig-Holstein Chancellery in 1806.
=== Food sourcing === In 1999, while looking for ways to improve the taste of the carnitas, founder Steve Ells was prompted by an article written by Edward Behr to visit Concentrated Animal Feeding Operations (CAFOs). Ells found the CAFOs "horrific", and began sourcing from open-range pork suppliers. This caused an increase in both the price and the sales of the carnitas burritos. In 2001, Chipotle released a mission statement called Food With Integrity, which highlighted Chipotle's efforts to increase their use of naturally raised meat, organic produce, and dairy without added hormones. Ells testified before the United States Congress in support of the Preservation of Antibiotics for Medical Treatment Act, which was aimed to reduce the amount of antibiotics given to farm animals. From 2006 to 2012, the Coalition of Immokalee Workers (CIW), a Floridian farmworker organization, protested Chipotle's refusal to sign a Fair Food agreement, which would commit the restaurant chain to pay a penny-per-pound premium on its Florida tomatoes to boost tomato harvesters' wages, and to only buy Florida tomatoes from growers who comply with the Fair Food Code of Conduct. In 2009, the creators of the documentary film Food, Inc.
=== Off-label drugs === α2-Adrenergic receptor agonists (e.g., clonidine, guanfacine) Anticonvulsants/mood stabilizers (e.g., valproic acid, lamotrigine) Antipsychotics (non-licensed) (e.g., haloperidol, olanzapine) Cannabinoids (e.g., cannabis, dronabinol, nabilone) Dietary supplements (e.g., N-acetylcysteine, omega-3 fatty acids, sulforaphane) Entactogens (serotonin releasing agents) (e.g., MDMA) Melatonin receptor agonists (e.g., melatonin) NMDA receptor antagonists (e.g., memantine, amantadine) Norepinephrine reuptake inhibitors (NRIs) (e.g., atomoxetine) Opioid receptor antagonists (e.g., naltrexone) Other antidepressants (e.g., mirtazapine) Oxytocin receptor agonists (e.g., oxytocin) Probiotics and prebiotics Psychostimulants (norepinephrine–dopamine releasing agents and/or reuptake inhibitors) (e.g., amphetamine, methylphenidate) Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, sertraline, citalopram) Serotonergic psychedelics (e.g., psilocybin, lysergic acid diethylamide (LSD)) Serotonin–norepinephrine reuptake inhibitors (SNRIs) (e.g., milnacipran) Serotonin releasing agents (e.g., fenfluramine—withdrawn and no longer recommended) Serotonin 5-HT1A receptor agonists (e.g., buspirone) Tricyclic antidepressants (TCAs) (e.g., clomipramine)
== Application == Due to the hemolytic toxicity of Guanacastepene A, it is not currently used directly in human clinical medicine. Its main potential, however, lies in its function as a "resistance breaker" against antibiotic-resistant pathogens, as various experiments have demonstrated its efficacy against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecalis (VRE). Furthermore, a more specific area of application arises in antifungal research, as newly isolated members of the guanacastane family, such as guanacastepene V, isolated from the marine fungus Coprinellus xanthothrix discovered on the surface of a barnacle off the coast of Japan (Kashima City), exhibit a selective effect against the yeast Candida auris. This species is considered an emerging multidrug-resistant yeast. Although guanacastepene V inhibits the growth of Candida auris with an MIC of 6.25 µg/ml, it also exhibits high selectivity, as it has virtually no effect on Candida albicans at an MIC of 100 µg/ml. Therefore, opportunities may arise to further develop other members of the guanacastane family to combat Candida albicans outbreaks in hospitals. Guanacastepene A also serves as a challenging target molecule for total chemical synthesis, making it useful for developing and testing novel synthetic methods; examples include the controlled fragmentation of cyclobutane rings or innovative variants of the Robinson annulation reaction for constructing complex seven-membered ring systems.
Sources: en.wikipedia.org
Fusion: In this method the ingredients are melted together in descending order of their melting points and stirred to ensure homogeneity. Trituration: In this finely subdivided insoluble medicaments are evenly distributed by grinding with a small amount of the base followed by dilution with gradually increasing amounts of the base.
=== Forensics === BRT's Forensics division offers services in serology screening, DNA profiling, and case review. These services are contracted by government agencies, defense counsel, and private citizens or organizations for several applications. Government agencies contract BRT’s Forensic division for criminal and “no-suspect” casework. The Laboratory offers STR analysis and Y-STR analysis with each of the commercial kits commonly used in the US. The Forensic division is accredited by ASCLD/Lab – International and meets the requirements of ISO/IEC 17025. BRT has also received accreditation from the Texas Department of Public Safety and has been approved by the Maryland State Police Forensic Science Division for analysis of casework that can be uploaded to CODIS. The Laboratory adheres to current Scientific Working Group on DNA Analysis Methods (SWGDAM) and FBI DNA Advisory Board (DAB) guidelines. Defense counsel contract BRT Laboratories to perform case reviews, which may include assistance with the interpretation of subpoena documents, sample retesting, and/or expert witness testimony. The Forensic division also provides serology and DNA profiling services to private citizens for infidelity testing and to private organizations or medical professionals for sample identity verification.
Flesinoxan (developmental code name DU-29373) is a potent and selective 5-HT1A receptor partial or near-full agonist of the phenylpiperazine class. Originally developed as a potential antihypertensive drug, flesinoxan was later found to possess antidepressant and anxiolytic effects in animal tests. As a result, it was investigated in several small human pilot studies for the treatment of major depressive disorder, and was found to have robust effectiveness and very good tolerability. It was also developed for treatment of anxiety disorders. The drug reached phase 3 clinical trials for anxiety disorders. However, due to "management decisions", the development of flesinoxan was stopped and it was not pursued any further. In humans, flesinoxan enhances REM sleep latency, decreases body temperature, and increases ACTH, cortisol, prolactin, and growth hormone secretion. In addition, both flesinoxan and LY-178210 induce anxiety in humans.
Immune checkpoint inhibitors: drugs that block immune system checkpoints to allow immune cells to respond more strongly to the cancer. T-cell transfer therapy: a treatment that takes T-cells from the tumor and selects or changes them in the lab to better attack cancer cells, then reintroduces them into the patient. Monoclonal antibodies: designed to bind to specific targets on cancer cells, marking cancer cells so that they will be better seen and destroyed by the immune system. Treatment vaccines: also known as therapeutic cancer vaccines, help the immune system learn to recognize and react to mutant proteins specific to the tumor and destroy cancer cells containing them. Immune system modulators: agents that enhance the body's immune response against cancer. Immunotherapies can be categorized as active or passive based on their ability to engage the host immune system against cancer. Active immunotherapy specifically targets tumor cells via the immune system. Examples include therapeutic cancer vaccines (also known as treatment vaccines, which are designed to boost the body's immune system to fight cancer), CAR-T cells, and targeted antibody therapies. In contrast, passive immunotherapy does not directly target tumor cells, but enhances the ability of the immune system to attack cancer cells. Examples include checkpoint inhibitors and cytokines. Active cellular therapies aim to destroy cancer cells by recognition of distinct markers known as antigens. In cancer vaccines, the goal is to generate an immune response to these antigens through a vaccine.
Sources: en.wikipedia.org
On 6 May 1978, Operation Reindeer was condemned by United Nations Security Council Resolution 428, which described it as a violation of Angola's territorial integrity and threatened punitive measures should the SADF attempt another incursion on Angolan soil. The resolution attracted almost unanimous support worldwide, and was endorsed not only by the Soviet Union, but by major Western powers such as the US, the UK, France, Canada, and West Germany. As the Cassinga incident received publicity, American and European attitudes became one of intense criticism of South African purpose as well as the process by which it carried out the war. Notably, Western pressure at the UN to recognise South Africa as an equal partner in any future Namibian peace settlement evaporated. Cassinga was a major political breakthrough for SWAPO, which had portrayed the casualties there as martyrs of a Namibian nation in the making. The movement received unprecedented support in the form of humanitarian aid sent to its remaining refugee camps and offers from foreign governments to educate refugees in their countries.
nuclear equivalence The principle that the nuclei of essentially all differentiated cells of a mature multicellular organism are genetically identical to each other and to the nucleus of the zygote from which they descended; i.e. they all contain the same genetic information on the same chromosomes, having been replicated from the original zygotic set with extremely high fidelity. Even though all adult somatic cells have the same set of genes, cells can nonetheless differentiate into distinct cell types by expressing different subsets of these genes. Though this principle generally holds true, the reality is slightly more complex, as mutations such as insertions, deletions, duplications, and translocations as well as chimerism, mosaicism, and various types of genetic recombination can all cause different somatic lineages within the same organism to be genetically non-identical.
The official language is Romanian, a Romance language (the most widely spoken of the Eastern Romance branch), which presents a consistent degree of similarity to Aromanian, Megleno-Romanian, and Istro-Romanian, but shares many features equally with the rest of the Western Romance languages, specifically Italian, French, Spanish, Portuguese, and Catalan. The Romanian alphabet contains the same 26 letters of the standard Latin alphabet, as well as five additional ones (namely ă, â, î, ț, and ș), totalling 31. Romanian is spoken as a first language by 91.55% of the entire population, while Hungarian and Vlax Romani are spoken by 6.28% and 1.20% of the population, respectively. There are also 40,861 native speakers of Ukrainian (concentrated in some compact regions near the border, where they form local majorities), 17,101 native speakers of Turkish, 15,943 native speakers of German, and 14,414 native speakers of Russian living in Romania. According to the Constitution, local councils ensure linguistic rights to all minorities. In localities with ethnic minorities of over 20%, that minority's language can be used in the public administration, justice system, and education. Foreign citizens and stateless persons who live in Romania have access to justice and education in their own language. English and French are the main foreign languages taught in schools. In 2010, the Organisation internationale de la Francophonie identified 4,756,100 French speakers in the country.
Sources: en.wikipedia.org
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.
The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.
It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.